B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SELE

MOLECULAR TARGET

selectin E

UniProt: P16581NCBI Gene: 64014 compounds

SELE (selectin E) is targeted by 4 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SELE

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Doxazosin0.691
2Ibotenic Acid0.691
3Oxyphenbutazone0.691
4Sialyl Lewis X Antigen0.691

About SELE as a Drug Target

SELE (selectin E) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 4 compounds with documented SELE interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SELE inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.